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Abstract
Enormous effort has been devoted to the development of a vaccine against human
immunodeficiency virus (HIV). But it is proving to be an unprecedented challenge to create an
effective vaccine mainly due to the high genetic variability of the virus and the necessity of cytotoxic
T lymphocytes (CTL) for containing the infection. Currently pursued vaccine strategies appear to
induce CTL in nonhuman primate models but in the early clinical trials, these strategies fail to fully
control the viral infection. New strategies that can cover the vast genetic diversity of HIV are
needed for the development of a potent vaccine.
Background
Since it was first reported in 1981, the disease has been
misrepresented in mass-media as gay scourge, drug-user's
Black Death, a punishment on sinful, etc. The list of
stigma goes on mainly due to the unique biology of the
causative agent which spreads both venereally and by con-
taminated blood products. The disease is caused by a ret-
rovirus of the Lentivirus genus under the name of Human
Immunodeficiency Virus (HIV-1). Once in the human
body, the virus replicates mainly in CD4+ lymphocytes
and leads to a progressive degenerative immune defi-
ciency disease, known as acquired immunodeficiency syn-
drome (AIDS). In just over two decades the virus has
killed more than 20 million humans and infected over 42
million people globally with the latest yearly infection
rate of over 6 million [1]. Considering the magnitude of
the HIV/AIDS epidemic, the efforts in fighting the disease
have been extraordinary through developing therapies
and potential vaccines. The literature is full with publica-
tions and reviews on the subject. Even a deadline has been
suggested by President Clinton in 1997 to develop a vac-
cine by 2007.
In its 2004 report, the AIDS Vaccine Advocacy Coalition
(AVAC) documented that there will not be a safe and
effective vaccine in 2007 and that we need to "focus on
the long haul and set an agenda for sustained and sustain-
able action that stretches well beyond 2007" [2]. The
problem is further compounded by the emergence of
drug-resistant variant strains that makes one ask the ques-
tion: is the replication machinery of HIV so unique that it
can easily find a way to evade the therapeutic and preven-
tive approaches, thus, making it difficult to develop a pre-
ventive measure against HIV/AIDS? In the following
sections I am looking into the unique biology of HIV
infection as an impediment to the preventive efforts
against HIV/AIDS and also into the possible strategies to
overcome such obstacle for developing a vaccine. This
article is not intended to be an exhaustive review of
research articles on HIV vaccine development. It summa-
rizes the difficult aspects of HIV vaccine development and
discusses prospects of novel vaccination strategies.
Uniqueness of HIV-1 infection
With a genome of approximately nine thousand nucle-
otides, HIV-1 has packaged the necessary information in
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overlapping open reading frames to encode 15 proteins
from multiply-spliced mRNAs (Figure 1) that provide the
unique characteristics to its infection. HIV establishes
infection (especially in CD4+ T lymphocytes) by integrat-
ing its genome into the host cell genome. The virus
spreads by either venereal contact, direct injection of con-
taminated blood products in the hematogenous circula-
tion or from mother to child during pregnancy or birth.
Therefore, any vaccine to be effective must induce
mucosal immunity to prevent venereal spread, and the
systemic immunity to control the other modes of trans-
mission. A successful vaccine would also be expected to
stimulate innate immune system, generate high titers of
neutralizing antibodies and strong cellular immune
responses leading to persistent and broad spectrum
immunity to cover all subtypes of HIV. The initial burst of
virus replication following the exposure appears to be
contained by a partial antiviral immune response, which
is not yet fully characterized. Despite this initial immune
response, HIV continues to replicate persistently in
infected individuals. The persistent replication in the pres-
ence of an immune response and integration of its genetic
material in the host genome are the most troubling
aspects of HIV-1 biology for developing a vaccine.
Additionally, the replication machinery of the virus is so
inaccurate that it generates new mutants for virtually every
virion produced in an infected individual, thus, creating a
myriad of new and unique viral particles every day [3]. A
high number of recombination events occurring during
the replication further compounds the genetic heteroge-
neity. It is this genetic diversity that also accounts for the
distinct subtypes or clades of HIV occurring in geographi-
cally distinct regions of the globe: for example, clade B
viruses cause AIDS epidemic predominantly in the West-
ern Hemisphere, clade C viruses in the sub-Saharan Africa
and clade B, C and E in Asian countries. The extraordinary
genetic variations create a heterogeneous virus popula-
tion, often termed as "swarm" or "quasi-species" in an
infected individual, which continually supplies new anti-
genic variants against which no immune response has yet
been developed. The mutant viruses keep continually
damaging or killing the cells of the immune system
(mainly CD4+  lymphocytes) and, thus progressively
Genome organization of HIV-1 Figure 1
Genome organization of HIV-1. The open reading frames for various polypeptides are shown as rectangles and the transcrip-
tion initiation site as an arrow. Multiply-spliced mRNA transcripts encoding various proteins are shown with splice-sites 
together with 5'-cap and 3' polyA tails. Major translated polypeptides from these mRNAs are finally processed to produce 15 
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destroy the body's ability to fight opportunistic infections
and certain cancers resulting in AIDS and finally death in
7 to 10 years.
The evolution of HIV is also believed to be the result of
genetic heterogeneity. A large number of lentiviruses exist
in African nonhuman primates as apathogenic species-
restricted simian immunodeficiency viruses (SIV) [4].
Wild populations of chimpanzees are infected with HIV-
like viruses which appear to have evolved through recom-
bination of distinct SIV isolates [5] and have zoonotically
infected humans to cause the AIDS epidemic [6]. SIV from
African monkeys also cause AIDS-like disease in Asian
macaques, which are used as nonhuman primate models
for understanding viral pathogenesis and evaluating vac-
cine strategies against HIV [7].
As mentioned above, a potent defense against HIV would
require both arms of the immune system: humoral and
cellular immunity. The protective role of HIV-neutralizing
antibodies in natural infection seems to be insufficient
since such antibodies are detected only after several weeks
of initial containment of virus replication. Moreover, only
low titers of neutralizing antibody are detected in HIV-1
infected individuals. Cellular immune responses seem to
have a dominant role in HIV-1 containment as evidenced
by several in vivo and in vitro observations: the emergence
of HIV-specific CD8+ CTL responses coincides with the
initial containment of viral replication in acute infections
[8]; high levels of HIV-specific CTL in the peripheral
blood of infected individuals are predictive of good clini-
cal status, measured by plasma viral RNA loads [9]; in vitro
replication of HIV-1 in CD4+ lymphocytes can be inhib-
ited by CD8+ lymphocytes possibly through direct cyto-
toxicity and other soluble factors including beta
chemokines [10,11]. The most compelling evidence of the
importance of CD8+ lymphocytes in controlling HIV rep-
lication came from animal models. Monkeys depleted of
CD8+  lymphocytes by administering anti-CD8 mono-
clonal antibodies were unable to control viral replication
upon infection with SIV. These animals died of AIDS-like
disease with an accelerated course [12].
Mutations have been shown to help HIV escape recogni-
tion by CTL [13]. Escape variants happen to be the cause
of an abrupt increase in viral replication and decreased
immune function in infected individuals. The daunting
challenge is to devise an immunogen that can induce
high-frequency CTL and antibody responses, which are
capable of neutralizing a variety of HIV isolates.
Failure of traditional preventive approaches
Traditional strategies for vaccination such as attenuated-
or inactivated-viruses, passive immunization and purified
or recombinant proteins (Figure 2) safely protect humans
against a variety of viral pathogens such as smallpox, mea-
sles, polio, rabies, hepatitis B virus, etc. These approaches
are not proving useful against HIV-1 due to the unique
biology of the infection and failure in eliciting potent
immune responses. A detailed overview of various vaccine
approaches has been compiled elsewhere [14].
In SIV-macaque models, gene-deleted SIV known to be
pathogenically attenuated were found to cause disease in
monkeys [15] and the degree of protection was found to
be inversely related to the level of attenuation [16]. Simi-
larly, humans who received blood products infected with
an HIV-1 isolate harboring a large genetic deletion
appeared initially to be free of disease but later developed
AIDS [17]. The animal models show that an attenuated
virus confers protection only if it can replicate at low but
consistent levels. However, even the low level of replica-
tion over prolonged periods might afford the virus time to
mutate and revert to pathogenic variants. The safety con-
cerns over this modality killed the enthusiasm among
investigators for pursuing it as a vaccine approach. Fur-
thermore, chemically inactivated virus vaccines have
induced effective immunity in monkeys against SIV [18].
However, this approach is very restricted in duration and
spectrum of immune response and fails to induce immu-
nity against genetically diverse viral isolates. Inactivated
vaccines also fail to generate CTL responses, thus, there is
little optimism that this approach will prove to be useful.
Nevertheless, non-infectious particle immunization strat-
egies are being pursued with the expectation that these
virus-like particles can be easily manipulated and are safer
than inactivated virus. Passive immunization studies,
mainly conducted in animal models, have not been
encouraging. Trkola et al. [19] evaluated the efficacy of
passively transferred neutralizing monoclonal antibodies
(2G12, 2F5 and 4E10) in suppressing viral rebound in
individuals undergoing interruption of antiretroviral ther-
apy. Such an approach would help prolong the life of
infected individuals but mass production of high-titer
monoclonal antibodies against variant strains may not be
a cost effective approach. Finally, highly purified viral pro-
teins expressed in mammalian or bacterial cells using
recombinant DNA technologies fail to induce CTL
responses or any immunity against genetically diverse HIV
isolates. Efficacy trials of such vaccines conducted in
United States and Thailand showed no protection against
HIV-1 [20]. The failure of traditional approaches asks for
exploring novel vaccine strategies against this virus. How-
ever, neutralizing monoclonal antibodies against HIV
hold some promise and their importance is discussed in
the following chapter.
Prospects of novel vaccination strategies
Live recombinant viral and bacterial vectors and plasmid
DNA have been explored as novel approaches for deliver-Virology Journal 2006, 3:60 http://www.virologyj.com/content/3/1/60
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ing HIV proteins as immunogens (Figure 2). Results of
several exciting studies in animal models employing these
novel approaches have been reviewed elsewhere [14]. The
plasmid DNA is known to be less immunogenic, particu-
larly in inducing CTL, in clinical testing in humans than
in animal models. Several improvements such as codon-
optimization for expression of viral proteins in mamma-
lian cells, alteration in regulatory elements, inclusion of
cytokine expressing genes and novel formulations with
polymers are being pursued to increase immunogenicity
of DNA vaccines.
Genes of HIV and SIV have also been expressed in micro-
organisms that have a proven record of being safe and
effective live-attenuated vaccines. A long list of such live
recombinant vectors includes attenuated vaccinia and
other pox-, alpha-, adeno- and measles viruses, attenuated
mycobacterium Bacille Calmette-Guerin, Salmonella,
Shigella and others. Since several of such vectors are repli-
cation competent, expression of HIV proteins from them
is expected to induce CTL. Many of the vaccine studies
combine various approaches in a prime-boost fashion for
avoiding immune responses to the vectors. Results of sev-
eral animal studies using these modalities have been
encouraging, but observations in early phase clinical trials
in humans have not been promising. Some of the trials
were stopped at various stages owing to adverse reactions
to the delivering vector or the inability of the expressed
immunogen to cover genetically diverse isolates prevalent
in the geographical areas. Nevertheless, the outcome of
several ongoing clinical trials is expected to deliver the
good news about safe vaccine delivery vectors and, if pos-
sible, an effective vaccine against a particular strain of
HIV-1 [21].
Some of the vaccine strategies against HIV currently under investigation are shown Figure 2
Some of the vaccine strategies against HIV currently under investigation are shown. The HIV virion with RNA and envelope 
(Env) glycoproteins gp41 and gp120 is also shown.Virology Journal 2006, 3:60 http://www.virologyj.com/content/3/1/60
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In anther approach, in vitro antigen-pulsed dendritic cells
(DC) upon re-injection show improvement in cellular
immune responses against the same HIV-1 strain [22].
This approach has potential as a therapeutic vaccine for
already ongoing HIV infections but is again limited in not
inducing immunity against genetically diverse isolates.
DC primed with a cocktail of peptides carrying diverse
immunogenic epitopes is an exciting avenue of investiga-
tion for inducing immunity against heterogeneous strains
of HIV-1. Although ex vivo loading of DC seems an excit-
ing avenue for individualized therapeutic intervention,
the financial cost of such an approach makes it unattrac-
tive endeavor for a prophylactic vaccine in developing
countries.
Lately, several neutralizing monoclonal antibodies have
been reported [23]. The neutralizing antibodies have
potential only if they are able to prevent the binding of
cell-free HIV virions to the receptor (CD4) and/or co-
receptor (CXCR4/CCR5) on the host cells, thus inhibiting
the entry of the virus. Two monoclonal antibodies (2F5
and 4E10) have been very recently demonstrated to bind
to membrane proximal linear epitopes of gp41 and
broadly neutralize HIV across clades [24]. The crystal
structure of the epitope-binding site of 4E10 has already
been determined [25]. This information is expected to
help design right immunogens that would induce 4E10-
like neutralizing antibodies and potentially prevent entry
of the virus in the host cells, thus halting further replica-
tion and transmission of HIV-1.
A vaccine for beating the genetic heterogeneity and 
antigenic diversity
The accumulated experience in vaccine development
against HIV highlights the challenge in devising an immu-
nogen that can mount a potent immune response against
the continuously arising viral variants and the AIDS epi-
demic. Using geographically prevalent strains or consen-
sus sequences have so far been the strategies for
developing vaccines against antigenic variants of HIV-1
[26]. Lately, clinical trials have also been initiated using
combinations of HIV-1 candidate vaccines with the idea
of combining the antigenic strength of each vaccine
against different clades [27]. The outcome of such combo
vaccines remains yet to be seen.
Easier said than done, one can think of utilizing the error-
prone replication machinery of HIV to generate potential
immunogens that would represent all the variants. In this
strategy, one would first replace the transcription-transac-
tivator Tat/TAR axis of HIV with controllable transcription
regulators and take out other non-structural protein genes
such as nef in order to weaken the virus. Several investiga-
tors have been pursuing the tetracycline/doxycycline-con-
trolled transcriptional regulator (tetO/tTA or tetO/rtTA)
systems [28,29]. This system could be used to generate
immunogens in vitro or in vivo. Since the system has also
been shown to have background expression [28], its in
vivo  utilization would require enhanced transcriptional
control. More stringency could be added to the system by
combining it with the tetO silencer (tTS) that would abro-
gate the background expression or leakiness [30]. The HIV
genome also has a size constraint for inserting additional
sequences. To circumvent this hurdle, multiple genomes
of HIV can be combined in parallel using the drug-con-
trolled transcription-transactivation system, thus com-
pensating for the insert size constraints and bringing the
system under stringent control. This way one would
expect to switch on or off the HIV replication machinery
in a controlled fashion and generate the necessary immu-
nogens for covering the genetic heterogeneity by utilizing
the error-prone HIV replication machinery itself. This
approach would need thorough investigation first in vitro
and later in animals using SIV as a model. The major con-
cerns over this approach would be recombination
between the multiple genomes of HIV resulting in patho-
genic variants. Moreover, if such viruses capture the cellu-
lar promoter/enhancer elements, the conditional
replication control would be lost resulting in a pathogenic
virus.
Alternatively, one can utilize the knowledge of human
genome and HIV sequences for creating "swarm or quasi-
species" in compu by digitally generating sequences of HIV
through combining all the possible substitutions at each
nucleotide position. The putative immunogens from such
sequence combinations would be identified by digitally
matching them to the three-dimensional structures of the
human MHC molecules (HLA) for the feasibility of CTL
epitopes presentable to the immune system. These
epitopes would be screened for their relevance to generate
CTL in vitro against the prevalent HIV strains. A cocktail of
such epitopes would be delivered using live-vectors or
primed-DC for generating protective immune responses
against the genetic variants. Similarly, putative neutraliz-
ing antibody inducing epitopes can also be generated uti-
lizing the information on antigen-binding sites of
neutralizing antibodies. These designer cocktails can be
readjusted through the digital data-base of prevalent vari-
ant viral sequences. Studies on representative or "immu-
nogenic consensus sequence" epitopes from multiple
viral variants using computer-driven methods are already
underway [31]. The major difficulty in this approach
could be the enormity of the size of the digital data-base
and servers needed to generate and analyze such epitopes
in compu, and the optimal delivery vehicles needed for the
cocktails. With the latest pledge from Microsoft® for help-
ing investigators to devise strategies against HIV [32], the
necessary expertise and digital data-base size appear not to
be the limiting factors. The expected positive outcomes ofVirology Journal 2006, 3:60 http://www.virologyj.com/content/3/1/60
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various vaccine approaches currently underway make me
believe that an optimal delivery vehicle would soon be
available. Given the right tools to combat the strength of
HIV in generating diversity, a safe and effective vaccine
against HIV/AIDS can be devised in the near future.
Conclusion
A tremendous amount of economic and intellectual effort
has already been invested in the pursuit of a vaccine
against HIV. The unique biology of HIV replication and
high rate of mutations have made it harder than initially
believed to come up with a preventive measure against
AIDS. With the technological advancements and con-
certed efforts from the policy makers and investigators, it
seems not far when a preventive vaccine would be availa-
ble against HIV.
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